131 related articles for article (PubMed ID: 23253441)
1. The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer's disease.
Li H; Qin J; Dhondi P; Zhou W; Vicarel M; Bara T; Cole D; Josien H; Pissarnitski D; Zhu Z; Palani A; Aslanian R; Clader J; Czarniecki M; Greenlee W; Cohen-Williams M; Hyde L; Song L; Zhang L; Chu I; Huang X
Bioorg Med Chem Lett; 2013 Jan; 23(2):466-71. PubMed ID: 23253441
[TBL] [Abstract][Full Text] [Related]
2. Triazoles as γ-secretase modulators.
Fischer C; Zultanski SL; Zhou H; Methot JL; Brown WC; Mampreian DM; Schell AJ; Shah S; Nuthall H; Hughes BL; Smotrov N; Kenific CM; Cruz JC; Walker D; Bouthillette M; Nikov GN; Savage DF; Jeliazkova-Mecheva VV; Diaz D; Szewczak AA; Bays N; Middleton RE; Munoz B; Shearman MS
Bioorg Med Chem Lett; 2011 Jul; 21(13):4083-7. PubMed ID: 21616665
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of pyrimido[4,5-c]azepine- and pyrimido[4,5-c]oxepine-based γ-secretase modulators.
Wu YJ; Zhang Y; Toyn JH; Macor JE; Thompson LA
Bioorg Med Chem Lett; 2016 Mar; 26(6):1554-1557. PubMed ID: 26898338
[TBL] [Abstract][Full Text] [Related]
4. γ-Secretase modulator in Alzheimer's disease: shifting the end.
Xia W; Wong ST; Hanlon E; Morin P
J Alzheimers Dis; 2012; 31(4):685-96. PubMed ID: 22710916
[TBL] [Abstract][Full Text] [Related]
5. Discovery of N-ethylpyridine-2-carboxamide derivatives as a novel scaffold for orally active γ-secretase modulators.
Sekioka R; Honda S; Honjo E; Suzuki T; Akashiba H; Mitani Y; Yamasaki S
Bioorg Med Chem; 2020 Jan; 28(1):115132. PubMed ID: 31767402
[TBL] [Abstract][Full Text] [Related]
6. Amino-caprolactam γ-secretase inhibitors showing potential for the treatment of Alzheimer's disease.
Neitzel ML; Aubele DL; Marugg JL; Jagodzinski JJ; Konradi AW; Pleiss MA; Szoke B; Zmolek W; Goldbach E; Quinn KP; Sauer JM; Brigham EF; Wallace W; Bova MP; Hemphill S; Basi G
Bioorg Med Chem Lett; 2011 Jun; 21(12):3715-20. PubMed ID: 21571529
[TBL] [Abstract][Full Text] [Related]
7. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
[TBL] [Abstract][Full Text] [Related]
8. Diamide amino-imidazoles: a novel series of γ-secretase inhibitors for the treatment of Alzheimer's disease.
Brodney MA; Auperin DD; Becker SL; Bronk BS; Brown TM; Coffman KJ; Finley JE; Hicks CD; Karmilowicz MJ; Lanz TA; Liston D; Liu X; Martin BA; Nelson RB; Nolan CE; Oborski CE; Parker CP; Richter KE; Pozdnyakov N; Sahagan BG; Schachter JB; Sokolowski SA; Tate B; Van Deusen JW; Wood DE; Wood KM
Bioorg Med Chem Lett; 2011 May; 21(9):2631-6. PubMed ID: 21269825
[TBL] [Abstract][Full Text] [Related]
9. Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease.
Mayer SC; Kreft AF; Harrison B; Abou-Gharbia M; Antane M; Aschmies S; Atchison K; Chlenov M; Cole DC; Comery T; Diamantidis G; Ellingboe J; Fan K; Galante R; Gonzales C; Ho DM; Hoke ME; Hu Y; Huryn D; Jain U; Jin M; Kremer K; Kubrak D; Lin M; Lu P; Magolda R; Martone R; Moore W; Oganesian A; Pangalos MN; Porte A; Reinhart P; Resnick L; Riddell DR; Sonnenberg-Reines J; Stock JR; Sun SC; Wagner E; Wang T; Woller K; Xu Z; Zaleska MM; Zeldis J; Zhang M; Zhou H; Jacobsen JS
J Med Chem; 2008 Dec; 51(23):7348-51. PubMed ID: 19012391
[TBL] [Abstract][Full Text] [Related]
10. Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond.
De Strooper B; Chávez Gutiérrez L
Annu Rev Pharmacol Toxicol; 2015; 55():419-37. PubMed ID: 25292430
[TBL] [Abstract][Full Text] [Related]
11. Discovery of fused 5,6-bicyclic heterocycles as γ-secretase modulators.
Qin J; Dhondi P; Huang X; Mandal M; Zhao Z; Pissarnitski D; Zhou W; Aslanian R; Zhu Z; Greenlee W; Clader J; Zhang L; Cohen-Williams M; Jones N; Hyde L; Palani A
Bioorg Med Chem Lett; 2011 Jan; 21(2):664-9. PubMed ID: 21195610
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 2-methylpyridine-based biaryl amides as γ-secretase modulators for the treatment of Alzheimer's disease.
Chen JJ; Qian W; Biswas K; Yuan C; Amegadzie A; Liu Q; Nixey T; Zhu J; Ncube M; Rzasa RM; Chavez F; Chen N; DeMorin F; Rumfelt S; Tegley CM; Allen JR; Hitchcock S; Hungate R; Bartberger MD; Zalameda L; Liu Y; McCarter JD; Zhang J; Zhu L; Babu-Khan S; Luo Y; Bradley J; Wen PH; Reid DL; Koegler F; Dean C; Hickman D; Correll TL; Williamson T; Wood S
Bioorg Med Chem Lett; 2013 Dec; 23(23):6447-54. PubMed ID: 24139583
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
Swahn BM; Kolmodin K; Karlström S; von Berg S; Söderman P; Holenz J; Berg S; Lindström J; Sundström M; Turek D; Kihlström J; Slivo C; Andersson L; Pyring D; Rotticci D; Ohberg L; Kers A; Bogar K; von Kieseritzky F; Bergh M; Olsson LL; Janson J; Eketjäll S; Georgievska B; Jeppsson F; Fälting J
J Med Chem; 2012 Nov; 55(21):9346-61. PubMed ID: 22924815
[TBL] [Abstract][Full Text] [Related]
14. An improved cell-based method for determining the γ-secretase enzyme activity against both Notch and APP substrates.
McKee TD; Loureiro RM; Dumin JA; Zarayskiy V; Tate B
J Neurosci Methods; 2013 Feb; 213(1):14-21. PubMed ID: 23219895
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel triazolobenzazepinones as γ-secretase modulators with central Aβ42 lowering in rodents and rhesus monkeys.
Fischer C; Zultanski SL; Zhou H; Methot JL; Shah S; Hayashi I; Hughes BL; Moxham CM; Bays NW; Smotrov N; Hill AD; Pan BS; Wu Z; Moy LY; Tanga F; Kenific C; Cruz JC; Walker D; Bouthillette M; Nikov GN; Deshmukh SV; Jeliazkova-Mecheva VV; Diaz D; Michener MS; Cook JJ; Munoz B; Shearman MS
Bioorg Med Chem Lett; 2015 Sep; 25(17):3488-94. PubMed ID: 26212776
[TBL] [Abstract][Full Text] [Related]
16. Advances in gamma-secretase modulation.
Pissarnitski D
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):392-402. PubMed ID: 17659480
[TBL] [Abstract][Full Text] [Related]
17. Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta.
Bakshi P; Jin C; Broutin P; Berhane B; Reed J; Mullan M
Bioorg Med Chem; 2009 Dec; 17(23):8102-12. PubMed ID: 19853461
[TBL] [Abstract][Full Text] [Related]
18. Discovery of γ-secretase modulators with a novel activity profile by text-based virtual screening.
Zettl H; Ness J; Hähnke V; Beher D; Jumpertz T; Saric A; Baumann K; Pietrzik CU; Bulic B; Schneider G; Weggen S
ACS Chem Biol; 2012 Sep; 7(9):1488-95. PubMed ID: 22725102
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of benzoazepinone-derived cyclic malonamides and aminoamides as potent gamma-secretase inhibitors.
Yang MG; Shi JL; Modi DP; Wells J; Cochran BM; Wolf MA; Thompson LA; Ramanjulu MM; Roach AH; Zaczek R; Robertson DW; Wexler RR; Olson RE
Bioorg Med Chem Lett; 2007 Jul; 17(14):3910-5. PubMed ID: 17502143
[TBL] [Abstract][Full Text] [Related]
20. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment.
Li T; Huang Y; Jin S; Ye L; Rong N; Yang X; Ding Y; Cheng Z; Zhang J; Wan Z; Harrison DC; Hussain I; Hall A; Lee DH; Lau LF; Matsuoka Y
J Neurochem; 2012 Apr; 121(2):277-86. PubMed ID: 22035227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
